ACC 2011-- Morten Schou, MD, PhD for the Danish Heart Failure Study


Dr. Morten Schou discusses the Danish Heart Failure Study and the conclusion that the researchers came up with upon evaluating the results.

Clyde Yancy, MD, FAHA, and Morten Schou, MD, PhD, spoke at the ACC 2011 meeting about the Danish Heart Failure Study. Schou, a cardiologists at one of the Copenhagen Medical Centers in Denmark discusses the findings from the study and the conclusions that the researchers came up with upon evaluating the results.

To start of with the discussion, Yancy said, "We have an ongoing questions in heart failure about hwo important it is to augment ordinary and standard therapy with either disease management as delivered by heart failure clinics, subspecialty clinics if you will. And or to overlay that process with either the risk strateficiation afforded by the assignment of biomarkers like anti pro-BNP possibly even including managing patients aggressively titrating thearpies according to the anti pro-BNP levels. Those are a lot of new wrinkles in the way we were considering taking care of patients with heart failure, but obviously all of these decisions need to be delivered by evidence."



Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
A panel of 5 cardiovascular experts
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
© 2024 MJH Life Sciences

All rights reserved.